-

Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in two upcoming virtual investor conferences as follows:

11th Annual LifeSci Partners Annual Corporate Access Event, January 5-7, 2022

Mr. Drysdale will participate in a panel discussion titled “Psychedelics: More Than Just a Trip” on Wednesday, January 5, 2022 at 10:00 a.m. ET. Please click here to register and access the webcast.

H.C. Wainwright Bioconnect Conference, January 10-13, 2022

Mr. Drysdale will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference being held virtually on Monday, January 10, 2022.

The fireside chat will be available on-demand beginning on January 10, 2022 at 7:00 a.m. ET. To listen to the event, please click here to register and access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Contacts

Investors & Media:
Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Industry:

Cybin Inc.

NYSEAM:CYBN
Release Summary
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
Release Versions
English

Contacts

Investors & Media:
Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

More News From Cybin Inc.

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. “Prepara...

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its third quarter ended December 31, 2024, and recent business highlights. “As we advance our lead clinical programs, CYB003 and CYB004, our focus in 2025 remains on continued...

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin’s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major De...
Back to Newsroom